Oncoinvent ASA (LTS:0RU5) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0RU5 Oncoinvent ASA LTS:0RU5
56 GF Score
Price kr80.00
GF Value kr969.74
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Oncoinvent ASA Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

LTS:0RU5
56GF Score
Oncoinvent ASA LTS:0RU5
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Oncoinvent ASA (LTS:0RU5) Overvalued in 2026?

Based on GuruFocus' analysis, Oncoinvent ASA stock appears to be undervalued. The current stock price of kr80.00 is trading 91.8% below its estimated GF Value™ of kr969.74. GuruFocus considers Oncoinvent ASA to be Possible Value Trap.

Key valuation signals for LTS:0RU5:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: kr969.74 vs. price of kr80.00 (91.8% below fair value)
  • GF Score™: 56/100 with 4 warning signs

No single metric tells the full story. See the LTS:0RU5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Oncoinvent ASA Business Description

Other Exchanges ONCIN:Norway7BG:Germany
Address Gullhaugveien 7, Oslo, NOR, 0484
Oncoinvent ASA is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. Its key product candidate is Radspherin, a receptor-independent alpha radiation therapy that leverages the anatomy of the abdominal cavity to destroy residual micrometastases using a single, localized dose of alpha radiation. Radspherin is currently in clinical development in two indications: peritoneal metastasis from ovarian and colorectal cancer, but it is also relevant for treating peritoneal metastasis from other cancer types and potentially metastatic cancer in other body cavities. Geographically, the company operates in Norway.
56GF Score

Get the complete analysis for LTS:0RU5

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr80.00
Price
kr969.74
GF Value